Welcome to our dedicated page for Matinas BioPharma Holdings news (Ticker: $MTNB), a resource for investors and traders seeking the latest updates and insights on Matinas BioPharma Holdings stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Matinas BioPharma Holdings's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Matinas BioPharma Holdings's position in the market.
Matinas BioPharma Holdings, Inc. announces that Chief Medical Officer, James J. Ferguson, will present two abstracts at the ASGCT Annual Meeting on the use of its lipid nanocrystal (LNC) platform for small oligonucleotide delivery. The presentations will focus on the uptake and targeted delivery of small oligonucleotides in innate immune cells and the successful in vivo oral delivery of therapeutic anti-inflammatory mRNA-targeted oligonucleotides using the LNC platform.
Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) will report first quarter 2024 financial results on May 9, 2024. The company, known for its lipid nanocrystal platform technology, will discuss financials and business updates in a webcast. Investors can participate in the conference call or webcast to gain insights into the company's performance.
Matinas BioPharma's oral formulation MAT2203, a less invasive treatment for mucormycosis, shows efficacy in treating fungal infections in mice. The study demonstrates prolonged survival, reduced fungal burden, and improved lung infection.
The promising results suggest that MAT2203 could be a safer alternative to current treatments, with potential benefits in treating various invasive fungal infections.
